ImmunityBio, Inc. (IBRX) Financial Statements
ImmunityBio, Inc. (IBRX) reported trailing twelve-month revenue of $165.8M (up 192.9% year on year) and net income of -$992.4M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$288.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IBRXImmunityBio, Inc.Follow IBRX — free
—
Price chart with a free account
- Market cap
- 8.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.2 | 0.0 | 0.0 | 0.0 | 2.2 | 0.6 | 0.9 | 0.2 | 0.6 | 14.7 | 113.3 | 165.8 | |
| Gross profit | — | — | — | — | — | — | — | — | 0.6 | 14.7 | 112.5 | — | |
| Research & development | 11.4 | 29.2 | 42.0 | 55.7 | 112.0 | 139.5 | 196.0 | 248.1 | 232.4 | 190.1 | — | — | |
| Operating income | — | -124.5 | -99.1 | -98.4 | -156.3 | -220.9 | -330.3 | -351.3 | -362.3 | -344.2 | -256.0 | -251.8 | |
| Pre-tax income | -237.2 | -121.4 | -96.9 | -96.7 | -160.3 | -226.0 | -349.8 | -417.3 | -583.9 | -413.6 | -351.6 | -992.6 | |
| Income tax | -0.3 | -0.6 | -0.5 | -0.5 | -0.1 | -1.8 | 0.0 | 0.0 | -0.0 | 0.0 | -0.1 | -0.2 | |
| Net income | -236.9 | -120.8 | -96.4 | -96.2 | -157.8 | -221.9 | -346.8 | -416.6 | -583.2 | -413.6 | -351.4 | -992.4 | |
| Diluted EPS ($) | -3.31 | -1.47 | -1.20 | -1.22 | -0.70 | -0.89 | -0.89 | -1.04 | -1.15 | -0.62 | -0.38 | -0.97 | |
| Diluted shares (mn) | — | — | — | — | — | — | 389.2 | 399.9 | 508.6 | 700.4 | 919.9 | — |
USD millions · SEC XBRL
ImmunityBio, Inc. — questions
- What is ImmunityBio, Inc.'s revenue?
- $165.8M over the twelve months to 2026-06-30, up 192.9% year on year, from its 10-Q and 10-K filings.
- What is ImmunityBio, Inc.'s net income?
- -$992.4M over the twelve months to 2026-06-30.
- What is ImmunityBio, Inc.'s free cash flow?
- -$288.5M over the twelve months to 2026-06-30.
- What are ImmunityBio, Inc.'s diluted earnings per share?
- $-0.97 over the twelve months to 2026-06-30.
Every figure on this page comes from ImmunityBio, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.